182 related articles for article (PubMed ID: 23525279)
21. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer.
Mesters JR; Barinka C; Li W; Tsukamoto T; Majer P; Slusher BS; Konvalinka J; Hilgenfeld R
EMBO J; 2006 Mar; 25(6):1375-84. PubMed ID: 16467855
[TBL] [Abstract][Full Text] [Related]
22. Clearance of amyloid-beta peptide by neuronal and non-neuronal cells: proteolytic degradation by secreted and membrane associated proteases.
Panchal M; Lazar N; Munoz N; Fahy C; Clamagirand C; Brouard JP; Dubost L; Cohen P; Brakch N; Rholam M
Curr Neurovasc Res; 2007 Nov; 4(4):240-51. PubMed ID: 18045149
[TBL] [Abstract][Full Text] [Related]
23. The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.
Evans JC; Malhotra M; Cryan JF; O'Driscoll CM
Br J Pharmacol; 2016 Nov; 173(21):3041-3079. PubMed ID: 27526115
[TBL] [Abstract][Full Text] [Related]
24. Novel substrate-based inhibitors of human glutamate carboxypeptidase II with enhanced lipophilicity.
Plechanovová A; Byun Y; Alquicer G; Skultétyová L; Mlčochová P; Němcová A; Kim HJ; Navrátil M; Mease R; Lubkowski J; Pomper M; Konvalinka J; Rulíšek L; Bařinka C
J Med Chem; 2011 Nov; 54(21):7535-46. PubMed ID: 21923190
[TBL] [Abstract][Full Text] [Related]
25. Heterologous amyloid seeding: revisiting the role of acetylcholinesterase in Alzheimer's disease.
Jean L; Thomas B; Tahiri-Alaoui A; Shaw M; Vaux DJ
PLoS One; 2007 Jul; 2(7):e652. PubMed ID: 17653279
[TBL] [Abstract][Full Text] [Related]
26. Alzheimer's Aβ
Leite JP; Gales L
FEBS Lett; 2019 Jan; 593(1):128-137. PubMed ID: 30403288
[TBL] [Abstract][Full Text] [Related]
27. Parallel Metabolomics and Lipidomics of a PSMA/GCPII Deficient Mouse Model Reveal Alteration of NAAG Levels and Brain Lipid Composition.
Sedlák F; Kvasnička A; Marešová B; Brumarová R; Dobešová D; Dostálová K; Šrámková K; Pehr M; Šácha P; Friedecký D; Konvalinka J
ACS Chem Neurosci; 2024 Apr; 15(7):1342-1355. PubMed ID: 38377674
[TBL] [Abstract][Full Text] [Related]
28. Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form.
Kanemitsu H; Tomiyama T; Mori H
Neurosci Lett; 2003 Oct; 350(2):113-6. PubMed ID: 12972166
[TBL] [Abstract][Full Text] [Related]
29. Degradation of beta-amyloid by proteolytic antibody light chains.
Rangan SK; Liu R; Brune D; Planque S; Paul S; Sierks MR
Biochemistry; 2003 Dec; 42(48):14328-34. PubMed ID: 14640701
[TBL] [Abstract][Full Text] [Related]
30. Rational design of urea-based glutamate carboxypeptidase II (GCPII) inhibitors as versatile tools for specific drug targeting and delivery.
Tykvart J; Schimer J; Bařinková J; Pachl P; Poštová-Slavětínská L; Majer P; Konvalinka J; Šácha P
Bioorg Med Chem; 2014 Aug; 22(15):4099-108. PubMed ID: 24954515
[TBL] [Abstract][Full Text] [Related]
31. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.
Bařinka C; Rojas C; Slusher B; Pomper M
Curr Med Chem; 2012; 19(6):856-70. PubMed ID: 22214450
[TBL] [Abstract][Full Text] [Related]
32. Ex vivo
Portelius E; Mattsson N; Pannee J; Zetterberg H; Gisslén M; Vanderstichele H; Gkanatsiou E; Crespi GA; Parker MW; Miles LA; Gobom J; Blennow K
Mol Neurodegener; 2017 Feb; 12(1):18. PubMed ID: 28219449
[TBL] [Abstract][Full Text] [Related]
33. Detection and quantitation of glutamate carboxypeptidase II in human blood.
Knedlík T; Navrátil V; Vik V; Pacík D; Šácha P; Konvalinka J
Prostate; 2014 May; 74(7):768-80. PubMed ID: 24647901
[TBL] [Abstract][Full Text] [Related]
34. Powering Amyloid Beta Degrading Enzymes: A Possible Therapy for Alzheimer's Disease.
Sikanyika NL; Parkington HC; Smith AI; Kuruppu S
Neurochem Res; 2019 Jun; 44(6):1289-1296. PubMed ID: 30806879
[TBL] [Abstract][Full Text] [Related]
35. A novel PSMA/GCPII-deficient mouse model shows enlarged seminal vesicles upon aging.
Vorlová B; Sedlák F; Kašpárek P; Šrámková K; Malý M; Zámečník J; Šácha P; Konvalinka J
Prostate; 2019 Feb; 79(2):126-139. PubMed ID: 30256431
[TBL] [Abstract][Full Text] [Related]
36. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents.
Kozikowski AP; Zhang J; Nan F; Petukhov PA; Grajkowska E; Wroblewski JT; Yamamoto T; Bzdega T; Wroblewska B; Neale JH
J Med Chem; 2004 Mar; 47(7):1729-38. PubMed ID: 15027864
[TBL] [Abstract][Full Text] [Related]
37. Regulation of glutamate carboxypeptidase II hydrolysis of N-acetylaspartylglutamate (NAAG) in crayfish nervous tissue is mediated by glial glutamate and acetylcholine receptors.
Urazaev AK; Grossfeld RM; Lieberman EM
J Neurochem; 2005 May; 93(3):605-10. PubMed ID: 15836619
[TBL] [Abstract][Full Text] [Related]
38. Glutamate carboxypeptidase II: an overview of structural studies and their importance for structure-based drug design and deciphering the reaction mechanism of the enzyme.
Pavlícek J; Ptácek J; Barinka C
Curr Med Chem; 2012; 19(9):1300-9. PubMed ID: 22304708
[TBL] [Abstract][Full Text] [Related]
39. Understanding molecular mechanisms of proteolysis in Alzheimer's disease: progress toward therapeutic interventions.
Higuchi M; Iwata N; Saido TC
Biochim Biophys Acta; 2005 Aug; 1751(1):60-7. PubMed ID: 16054018
[TBL] [Abstract][Full Text] [Related]
40. Measurement of glutamate carboxypeptidase II (NAALADase) enzyme activity by the hydrolysis of [³H]-N-acetylaspartylglutamate (NAAG).
Tiffany CW; Slusher BS
Curr Protoc Pharmacol; 2002 Feb; Chapter 3():Unit3.10. PubMed ID: 21959764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
